Martin, L. K., Li, X., Kleiber, B., Ellison, E. C., Bloomston, M., Zalupski, M., & Bekaii-Saab, T. S. (2012). VEGF remains an interesting target in advanced pancreas cancer (APCA): Results of a multi-institutional phase II study of bevacizumab, gemcitabine, and infusional 5-fluorouracil in patients with APCA. Oxford University Press.
Citação norma ChicagoMartin, L. K., X. Li, B. Kleiber, E. C. Ellison, M. Bloomston, M. Zalupski, and T. S. Bekaii-Saab. VEGF Remains an Interesting Target in Advanced Pancreas Cancer (APCA): Results of a Multi-institutional Phase II Study of Bevacizumab, Gemcitabine, and Infusional 5-fluorouracil in Patients With APCA. Oxford University Press, 2012.
Citação norma MLAMartin, L. K., et al. VEGF Remains an Interesting Target in Advanced Pancreas Cancer (APCA): Results of a Multi-institutional Phase II Study of Bevacizumab, Gemcitabine, and Infusional 5-fluorouracil in Patients With APCA. Oxford University Press, 2012.